IRLAB Therapeutics 将来の成長

Future 基準チェック /16

IRLAB Therapeutics収益と収益がそれぞれ年間59.6%と6.3%増加すると予測されています。

主要情報

59.6%

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長	48.5%
収益成長率	6.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	12 May 2025

今後の成長に関する最新情報

Recent updates

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

Mar 18

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

Dec 01

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

May 19

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Sep 11

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Apr 30

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Mar 19

We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth

Jan 25

Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay

Dec 21

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Nov 25

業績と収益の成長予測

OM:IRLAB A - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	135	12	N/A	N/A	1
12/31/2026	48	-54	N/A	N/A	2
12/31/2025	21	-53	N/A	-55	1
3/31/2025	99	-78	-21	-21	N/A
12/31/2024	95	-83	-66	-66	N/A
9/30/2024	51	-113	-77	-77	N/A
6/30/2024	42	-119	-109	-109	N/A
3/31/2024	6	-157	-162	-162	N/A
12/31/2023	6	-178	-165	-165	N/A
9/30/2023	19	-176	-169	-169	N/A
6/30/2023	36	-162	-163	-160	N/A
3/31/2023	52	-144	-155	-151	N/A
12/31/2022	61	-113	-146	-143	N/A
9/30/2022	61	-103	-136	-133	N/A
6/30/2022	240	42	96	98	N/A
3/31/2022	217	43	117	118	N/A
12/31/2021	208	52	128	129	N/A
9/30/2021	196	55	140	141	N/A
6/30/2021	0	-93	-93	-92	N/A
3/31/2021	N/A	-93	-88	-87	N/A
12/31/2020	0	-92	-90	-89	N/A
9/30/2020	0	-99	-99	-99	N/A
6/30/2020	0	-93	-93	-92	N/A
3/31/2020	1	-98	-98	-98	N/A
12/31/2019	0	-96	-91	-91	N/A
9/30/2019	1	-88	-83	-83	N/A
6/30/2019	1	-83	-78	-78	N/A
3/31/2019	0	-76	-75	-75	N/A
12/31/2018	0	-74	N/A	-71	N/A
9/30/2018	0	-68	N/A	-75	N/A
6/30/2018	0	-73	N/A	-67	N/A
3/31/2018	0	-60	N/A	-58	N/A
12/31/2017	0	-56	N/A	-58	N/A
9/30/2017	0	-58	N/A	-48	N/A
6/30/2017	0	-48	N/A	-45	N/A
3/31/2017	3	-44	N/A	-45	N/A
12/31/2016	3	-43	N/A	-41	N/A
12/31/2015	3	-12	N/A	-28	N/A
12/31/2014	3	3	N/A	-11	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IRLAB A今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IRLAB A今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: IRLAB A今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IRLAB Aの収益 ( 6.3% ) Swedish市場 ( 4.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: IRLAB Aの収益 ( 6.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IRLAB Aの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/05/16 23:19
終値	2025/05/16 00:00
収益	2025/03/31
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

IRLAB Therapeutics AB (publ) 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。4

アナリスト	機関
Gonzalo Artiach Castanon	ABG Sundal Collier Sponsored
null null	ABG Sundal Collier Sponsored
Jyoti Prakash	Edison Investment Research

IRLAB Therapeutics 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Price target decreased by 12% to kr53.60

Price target decreased by 7.1% to kr56.63

Price target increased by 8.0% to kr60.95

Consensus revenue estimates increase by 178%

Consensus revenue estimates increase by 88%

Price target increased by 83% to kr59.05

Recent updates

Health Check: How Prudently Does IRLAB Therapeutics (STO:IRLAB A) Use Debt?

New minor risk - Profitability

Price target decreased by 12% to kr53.60

New major risk - Financial position

IRLAB Therapeutics AB Publishes Phase IIb Data on Mesdopetam in Movement Disorders Clinical Practice

New major risk - Revenue and earnings growth

IRLAB Therapeutics AB Announces Positive Topline Results from Its Phase I Clinical Study with the Drug Candidate Irl757 in Healthy Adults Aged 65 Years and Older

New minor risk - Share price stability

IRLAB Therapeutics AB Announces All Patients Enrolled in the Phase IIb Study with the Drug Candidate Pirepemat (REACT-PD)

IRLAB Therapeutics AB (publ), Annual General Meeting, May 21, 2025

New minor risk - Profitability

IRLAB Therapeutics AB (publ) to Report Q2, 2025 Results on Jul 09, 2025

Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?

IRLAB Therapeutics AB Receives Milestone Payment of USD 2.5 Million in Conjunction with First Dosing in A Phase I Study with IRL757 in Healthy Adults

IRLAB Therapeutics AB Announces Positive Data from the First Part of Phase I Study with the Drug Candidate IRL 757

IRLAB Therapeutics AB (publ) Granted Additional Patent for Its Drug Candidate Pirepemat Expanding the Patent Protection in the US

New minor risk - Profitability

IRLAB Therapeutics AB Announces Phase IIb Study of Pirepemat Can Proceed as Planned After Positive Opinion from External Safety Committee

Price target decreased by 7.1% to kr56.63

IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?

IRLAB Therapeutics AB (publ) Announces CEO Changes, Effective from August 1, 2024

IRLAB Therapeutics AB (publ) Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757

Price target increased by 8.0% to kr60.95

Consensus revenue estimates increase by 178%

Director recently bought kr260k worth of stock

IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757

New major risk - Financial position

IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam

Consensus revenue estimates increase by 88%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

IRLAB Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Apr 29, 2024

IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines

Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation

IRLAB Therapeutics AB's Drug Candidate IRL757 Completes all Preclinical Studies and Development Work Necessary to Start Phase I

IRLAB Therapeutics AB (publ) Submits Request for an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program

IRLAB Therapeutics AB Receives Additional Patent for Drug Candidate Pirepemat That Expands its Patent Protection

New minor risk - Profitability

IRLAB Therapeutics AB (publ) Announces Appointment to its Nomination Committee

Third quarter 2023 earnings released

IRLAB Therapeutics AB (publ) to Report Q1, 2024 Results on May 08, 2024

Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely

Price target increased by 83% to kr59.05

Second quarter 2023 earnings released

IRLAB Secures Full Ownership of the Mesdopetam Project and Continues Product Development

Less than half of directors are independent

IRLAB Therapeutics AB (publ) Elects Christer Nordstedt, Daniel Johnsson and Veronica Wallin as Board Members

IRLAB Therapeutics AB Announces That All Participating Study Sites in the Phase IIb Study of Pirepemat (IRL752) Are Activated and Recruiting Patients

IRLAB Therapeutics AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

IRLAB Therapeutics Updates on Portfolio Development Milestones

IRLAB Therapeutics Announces Top-Line Results from Phase IIb Trial of Mesdopetam (IRL790) in Parkinson’s Disease

IRLAB Therapeutics AB Nominates IRL1117 as Drug Candidate from the P003 Project to Develop a Novel Treatment for Parkinson's Disease

IRLAB Therapeutics AB Reports Last Patient Last Visit (“Lplv”) Achieved in Phase Iib Clinical Study of Mesdopetam in Pd-Lids with Top-Line Results Anticipated Mid-January 2023

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

IRLAB Therapeutics AB (publ) to Report Q1, 2023 Results on May 10, 2023

IRLAB Therapeutics AB Announces New Preclinical Data Indicating Phase IIb Drug Candidate Mesdopetam's Powerful Efficacy in Parkinson's Psychosis and PD-LIDs

IRLAB Therapeutics AB (publ) Appoints Nomination Committee Ahead of Annual General Meeting 2023

IRLAB Completes Recruitment in Phase IIb Study of Mesdopetam (IRL790) in Patients with Parkinson's Levodopa-Induced Dyskinesias

Consensus forecasts updated

IRLAB's Partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan

Consensus forecasts updated

Irlab Therapeutics AB (Publ) Expands Phase IIb/III Pd-Lids Study with Mesdopetam to Support Phase Iii Program and Expects Completion of Enrollment During the Summer

IRLAB Therapeutics AB (publ) Appoints Richard Godfrey as CEO, Effective from 1 July 2022

Chief Financial Officer recently bought kr407k worth of stock

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

IRLAB Therapeutics AB (publ) Approves Board Appointments

Price target increased to kr69.50

Insufficient new directors

Insufficient new directors